Epidarex Capital — Pre-Seed & Seed VC Firm
Epidarex Capital is a Pre-Seed, Seed, Series A venture capital firm based in Edinburgh, Scotland investing in Healthcare. The firm has 29 portfolio companies in our records.
- Portfolio
- 29 companies on record
- Partners
- 8 listed
- AUM
- $250M
- Stage
- Pre-Seed, Seed, Series A
- Sectors
- Healthcare
- HQ
- Edinburgh, Scotland
- Check size
- Not in our records
Last verified: 2026-11-10
Pre-Seed, Seed, Series A
$250M
29+ companies
8 partners
Investment Thesis
Early-stage venture firm focused on building breakthrough life science companies in emerging academic hubs. The strategy emphasizes specialist life science investing outside the usual coastal US power centers.
How Epidarex Capital invests
Epidarex Capital is a vc firm based in Edinburgh, Scotland. The firm invests at the Pre-Seed, Seed, Series A stages, with a focus on Healthcare.
Epidarex Capital manages approximately $250M in assets. Our records include 4 funds raised by the firm.
Epidarex Capital has backed 29 companies in our records, including AdoRx Therapeutics, Apellis Pharmaceuticals, Caldan Therapeutics.
Partners & Team
Industry Focus
Invests In
Funds
Epidarex Capital Fund IV
Epidarex Capital Fund III
Epidarex Capital Fund II
Epidarex Capital Fund I
Recent Activity
Raised Epidarex Capital Fund IV ($150M)
2019 · fund records
Raised Epidarex Capital Fund III ($150M)
2015 · fund records
Raised Epidarex Capital Fund II ($100M)
2011 · fund records
Raised Epidarex Capital Fund I ($100M)
2007 · fund records
Portfolio Companies (29)
Other
AdoRx Therapeutics
AdoRx is developing new modulators of the adenosine pathway for the treatment of cancer.
Apellis Pharmaceuticals
Apellis is a NASDAQ listed company developing therapies for a broad range of debilitating diseases that are driven by uncontrolled or excessive activation of the complement cascade.
Caldan Therapeutics
Caldan is developing novel therapeutics targeting free fatty acid receptors for metabolic diseases.
Clyde Biosciences
Clyde Biosciences has developed a pioneering technology (CellOPTIQ) to rapidly evaluate cardiotoxicity risk in pharmaceuticals.
Confluence Life Sciences
A technology-based company focusing on rational drug design to identify novel drugs for cancer and chronic inflammatory diseases.
Curve Therapeutics
Curve is deploying its Microcycle platform to build a pipeline of first-in-class therapeutics targeting protein-protein interactions.
DUNAD Therapeutics
Dunad is focusing on the development of next-generation small molecule therapeutics based on its highly differentiated, tuneable and targeted protein degradation technology.
Edinburgh Molecular Imaging
EM Imaging is a clinical phase biotechnology company with a highly novel C-Met molecular targeting technology platform.
Enterprise Therapeutics
Enterprise Therapeutics is dedicated to the research and development of novel therapies for the treatment of respiratory diseases.
Epsilogen
Epsilogen is developing IgE-based antibody therapeutics for the treatment of cancer.
- •Raising at Pre-Seed, Seed, Series A? You're squarely in their sweet spot.
- •Lead with your fit in Healthcare — the sectors they actively back.
- •warm intro preferred
- •Address your outreach to a specific partner, such as Rachel Haynes, Operations Manager.
- •A warm introduction beats a cold email. Get matched and request an intro.
Featured In
Browse More Investors
Fundraising resources
Frequently Asked Questions
See if Epidarex Capital is a match for your startup
Upload your pitch deck to see how well you match with Epidarex Capital and 10,000+ other investors.
Ask your AI assistant about this investor: connect InvestorMatch to Claude or ChatGPT
Is this your profile? Request a correction or removal